News

Specifar is a third-party product developer, with approximately 400 marketing authorizations licensed to third parties for sale in 36 countries, mainly in Europe. It has eight products currently

In working with the MAVERIC team, Recombinant uses its Agile Iterative Development approach to design and prototyping, and delivering production systems in a just-in-time mode to meet the

The study assessed around 168 healthy subjects to investigate the safety and preliminary immunogenicity in the different age groups. The preliminary immunogenicity results demonstrated that the vaccine has

The trial was designed to investigate the safety profile of MS1819 and to get early evidence of the clinical activity of the MS1819 recombinant lipase in patients who

Mylan has launched the drug under its development and supply agreement with Coastal Pharmaceuticals. Oxycodone Hydrochloride (HCI) tablets USP, 5mg, 15mg and 30mg are the generic version of

Wheeler will succeed Gerard Barba, who will continue his work as the chairman of the board of directors Before joining Marken, Wheeler served as the president and CEO

An analysis of the weight loss dietary supplement by the FDA found that the product contains undeclared Sibutramine, not approved by the agency, and therefore the safety and

The FDA’s decision allows the company to start a Phase 1 clinical trial of PWT33597, a proprietary, selective, dual inhibitor of PI3K kinase alpha and mTOR. The Phase

Avanafil is a highly selective phosphodiesterase type 5 (PDE5) inhibitor licensed from Mitsubishi Tanabe Pharma. The study evaluated the safety and efficacy of avanafil as a treatment of